---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-23-012576"
form_type: "8-K"
ticker: "PBYI"
cik: "0001401667"
company_name: "PUMA BIOTECHNOLOGY, INC."
filed_at: "2023-05-04T23:59:59+00:00"
generated_at: "2026-06-15T21:30:41.420561+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Puma Biotech Q1 net income $1.4M vs loss; NERLYNX revenue $46.8M (+15% YoY)

## Summary
- GAAP net income $1.4M ($0.03/diluted share) vs net loss of $3.4M in Q1 2022.
- Non-GAAP adjusted net income $4.2M ($0.09/share) vs adjusted net loss of $0.3M.
- Q1 product revenue (NERLYNX) $46.8M, up from $40.7M YoY; royalty revenue $6.0M.
- Cash and marketable securities $71.2M at March 31, 2023 vs $81.1M at Dec 31, 2022.
- Guidance: FY 2023 net product revenue $205-210M; net income $20-24M.

## SEC filing metadata
- accession: 0001437749-23-012576
- form_type: 8-K
- ticker: PBYI
- cik: 0001401667
- company_name: PUMA BIOTECHNOLOGY, INC.
- filed_at: 2023-05-04T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1401667/000143774923012576/0001437749-23-012576-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1401667/000143774923012576/pbyi20230502_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-23-012576
- JSON: https://secwatch.observer/filing/0001437749-23-012576.json
- Plain text: https://secwatch.observer/filing/0001437749-23-012576.txt

## Key facts
- Earnings Releases
  PUMA BIOTECHNOLOGY, INC. reported first quarter ended March 31, 2023 results: revenue $46.8 million, net income $1.4 million, EPS $0.03 per basic and diluted share.
  - Period: first quarter ended March 31, 2023
  - Revenue: $46.8 million
  - Net income: $1.4 million
  - EPS: $0.03 per basic and diluted share
  - Result: reported results
  source text: Product revenue, net in the first quarter of 2023 was $46.8 million, compared to product revenue, net of $40.7 million in the first quarter of 2022. Based on accounting principles generally accepted in the United States (GAAP), Puma reported net income of $1.4 million, or $0.03 per basic and diluted share, for the first quarter of 2023, compared to net loss of $3.4 million, or $0.08 per share, for the first quarter of 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1401667/000143774923012576/0001437749-23-012576-index.htm
- Earnings Releases
  PUMA BIOTECHNOLOGY, INC. reported full year 2023 results: revenue $205 - $210 million, net income $20 - $24 million. Guidance initiated.
  - Period: full year 2023
  - Revenue: $205 - $210 million
  - Net income: $20 - $24 million
  - Guidance: initiated
  - Result: guidance update
  source text: Second Quarter 2023 Full Year 2023 Net Product Revenue $47 - $50 million $205 - $210 million Royalty Revenue $2 - $3 million $25 - $30 million Net Income/(Loss) $0 - $1.5 million $20 - $24 million Gross to Net Adjustment 20% - 21% 19% - 20%
  evidence_url: https://www.sec.gov/Archives/edgar/data/1401667/000143774923012576/0001437749-23-012576-index.htm
- Earnings Releases
  PUMA BIOTECHNOLOGY, INC. reported second quarter 2023 results: revenue $47 - $50 million, net income $0 - $1.5 million. Guidance initiated.
  - Period: second quarter 2023
  - Revenue: $47 - $50 million
  - Net income: $0 - $1.5 million
  - Guidance: initiated
  - Result: guidance update
  source text: Second Quarter 2023 Full Year 2023 Net Product Revenue $47 - $50 million $205 - $210 million Royalty Revenue $2 - $3 million $25 - $30 million Net Income/(Loss) $0 - $1.5 million $20 - $24 million Gross to Net Adjustment 20% - 21% 19% - 20%
  evidence_url: https://www.sec.gov/Archives/edgar/data/1401667/000143774923012576/0001437749-23-012576-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.